_1777294237270_124456903.png&w=64&q=75){kind=small}
Blindness prompts legal action over slimming injections
Medications known for weight loss and diabetes treatment, such as Ozempic, Wegovy, and Mounjaro, have raised new concerns regarding their potential association with a rare and sudden vision loss condition called non-arteritic ischemic optic neuropathy (NAION). Dozens of individuals in the United States have filed lawsuits against the manufacturers, accusing them of failing to provide adequate warnings about the risk of developing this condition, which can lead to a sudden and permanent loss of vision. Meanwhile, the Saudi Food and Drug Authority announced measures to reduce the risk of this condition, indicating that existing evidence suggests a possible causal link between these drugs and optic nerve damage. The condition is classified as extremely rare, with European data estimating its occurrence at approximately 10 cases per 10,000 people taking the medication over one year. Research is still ongoing to confirm the direct cause.
Notice: This Is an AI-Generated Summary
Comments (0)